Garantie de satisfaction à 100% Disponible immédiatement après paiement En ligne et en PDF Tu n'es attaché à rien
logo-home
Samenvatting Advanced Microbiology €7,16
Ajouter au panier

Resume

Samenvatting Advanced Microbiology

 13 vues  0 fois vendu

Samenvatting van de lessen advanced microbiology. Met het leren van dit document ben ik geslaagd voor het examen. Format is in bulletpoints met veel figuren

Aperçu 4 sur 89  pages

  • 16 mars 2024
  • 89
  • 2023/2024
  • Resume
Tous les documents sur ce sujet (1)
avatar-seller
DCsss
Advanced Microbiology
Topic one: Use of bacteria in cancer therapy
1.1 Cancer – general information
1.1.1 Cancer burden in Belgium
• 2020: 77827 new diagnoses of cancer (♂: 54,2%)
o Highest incidence ♂: prostate cancer
o Highest incidence ♀: breast cancer
• Prostate, beast , lung and colorectal cancer
o 45% of the new diagnoses
• Highest mortality
o ♂: lung cancer
o ♀: breast cancer
1.1.2 Cancer definitions
Cancer: a malignant neoplasm in which cells are;
• Aggressive: cells grow and divide without respect to normal limits
• Invasive: cells invade and destroy adjacent tissues
• And/or metastatic: cells spread to other body locations
Tumor: a solid neoplasm
• Benign tumor: self-limiting growth, no invasion in tissues nor metastasis
• Malignant tumor: with characteristics of cancer (~80% of cancers)
Neoplasm: abnormal proliferation of genetically altered cells (benign or malignant)
1.1.3 Tumor types
Carcinoma:
• Malignant tumors: cells of ecto- or endodermal origin
o Ectodermal: the outer layer of the skin
o Endodermal: innermost of the three primary germ layers
• Most common cancers: breast, prostate, lung, colon and skin
Sarcoma:
• Malignant tumors: cells of mesodermal origin
o Connective, supportive or soft tissues
• Tumors related to bone, cartilage, fat, muscle and blood vessels
• Very rare → 1% of the cancers
1.1.4 Treatment modalities of tumors
• Conventional treatments
o Surgery
o Radiotherapy
o Chemotherapy
o Immunotherapy (most recent)
• Limitations of these treatments
o Surgery
▪ Inadequate removal of total tumor
▪ Existence of micro-extensions/-metastases
o Radio- and chemotherapy
▪ Tumor targeting
▪ Severe side effects
▪ Resistance of tumor cells to damaging agents
o Immunotherapy
▪ Still in its infancy
▪ Personalized medicine


1

,1.1.5 Tumor growth
• Tumor cell proliferation requires blood vessels to provide nutrients
o Neo-angiogenesis
• Tumor growth vs. vessel proliferation often impaired
o Aberrant blood vessel structure
▪ Irregular, blind ends, arteriovenous shunts
o Irregular blood flow
▪ Disturbed delivery of oxygen and nutrients
▪ Hypoxia and cell death → setting free cell debris (DNA and proteins)




Figure 1 Irregular tumor vasculature. Left - Normal tissue. Right - Tumor tissue, due to fast angiogenesis many mistakes are made .
Endothelial cells not fixed very well to each other causing leaks, holes and obstruction

1.1.6 Hypoxia in tumors




Figure 2. Hypoxia in tumor cells, blue is hypoxic and red is oxygenated

• Tumor has different regions
• Blood vessels go inside the clumb of tumor cells
o Some parts are closer to a blood vessel → better oxygenation
o Other parts suffer from anoxic/hypoxic conditions
• Anoxic/necrotic regions spread throughout tumor mass
1.1.6.1 Hypoxia: cause of intrinsic resistance
◆ Radiation resistance
• Hypoxic cells need stronger radio therapy than oxygenated cells
• Hypoxic cells are 3 times more resistant than aerobic cells
2

,◆ Drug resistance
• Hypoxic cells are not reached by drugs
o No blood vessels → drug cannot get there
• Chemotherapeutics often targeted at well-proliferating cells
o Less effective in hypoxic, non-proliferating cells
• Solution: hypoxia-induced prodrugs
• Ex. Tirapazamine (TPZ)
o Selective cytotoxicity in hypoxic mammalian cells




Figure 3 Tirapazamine. Hypoxia induced prodrug

1.1.6.2 Hypoxia: cause of molecular resistance
• Hypoxia-mediated induction of genetic and metabolic changes un tumor cells
o Hypoxia tolerance regulated by several pathways
o Hypoxia-inducible factor (HIF-1) pathway
• More malignant phenotype
o Induction of metastasis
o Increase of neo-angiogenesis
o Selection of cells with diminished apoptotic potential
•  Accompanied by molecular therapy resistance
1.1.7 Alternative treatment modalities
• Gene therapy: introduction of therapeutic genes in tumor cells
• Protein therapy: delivery of therapeutic proteins to tumor cells
• Cancer immunotherapy: modulation of immune response to treat cancer
• Cancer vaccines: treatment or prevention of cancer by providing tumor antigens
• More effective drugs delivered by alternative mechanisms
1.2 Bacteria and cancer: cause or cure?
1.2.1 Helicobacter pylori as causative agent
• Acute H. pylori can evolve to chronic H. pylori infection
• May cause MALT lymphoma or gastric cancer




Figure 4 Evolution of Helicobacter pylori infection
3

, 1.2.2 Other bacteria associated with cancer
Streptococcus bovis
Colorectal cancer Bacteroides fragilis
Fusobacterium nucleatum
Gallbladder cancer Salmonella Typhi
Lung cancer Chlamydophilia pneumoniae
Esophageal cancer Streptococcus anginosus
Capnocytophaga gingivalis
Oral squamous cell carcinoma Prevotella spp.
Streptococcus mitis
Leukemia, lung cancer Mycoplasma
1.3 Bacterial approaches in cancer treatment
1.3.1 Experiences from the past
• 1831: cancer cure in patients suffering from Clostridium perfringens infection (gas gangrene)
o 1947: first injection of Clostridium spores to treat cancer
• Early 19th century: tumor regression/cancer cure upon Streptococcus pyogenes infection (erysipelas)
o “Coley’s toxin”: inactivated streptococci and Serratia marcescens
o Basis of cancer immunotherapy
• Late 19th century: lower frequency of cancer in tuberculosis patients
o 1921: isolation of attenuated Mycobacterium bovis strains
o 1970: BCG (Bacillus Calmette-Guerin) vaccine for bladder cancer
1.3.2 Bacterial DNA
• Unmethylated CpG sequences are 20x more in bacteria (and viruses) than mammalian DNA
• CpG motifs = PAMPs (pathogen associated molecular patterns)
• Endocytosed CpG motifs are recognized by toll-like-receptor 9 in plasmacytoid dendritic- and B-cells
• TLR9 activation → immunostimulation
o Bypass tumor-induced suppression of immune response
o Shift from T cell tolerance to strong cytotoxic T cell response against tumor antigens




Figure 5. Bacterial CpG motifs




4

Les avantages d'acheter des résumés chez Stuvia:

Qualité garantie par les avis des clients

Qualité garantie par les avis des clients

Les clients de Stuvia ont évalués plus de 700 000 résumés. C'est comme ça que vous savez que vous achetez les meilleurs documents.

L’achat facile et rapide

L’achat facile et rapide

Vous pouvez payer rapidement avec iDeal, carte de crédit ou Stuvia-crédit pour les résumés. Il n'y a pas d'adhésion nécessaire.

Focus sur l’essentiel

Focus sur l’essentiel

Vos camarades écrivent eux-mêmes les notes d’étude, c’est pourquoi les documents sont toujours fiables et à jour. Cela garantit que vous arrivez rapidement au coeur du matériel.

Foire aux questions

Qu'est-ce que j'obtiens en achetant ce document ?

Vous obtenez un PDF, disponible immédiatement après votre achat. Le document acheté est accessible à tout moment, n'importe où et indéfiniment via votre profil.

Garantie de remboursement : comment ça marche ?

Notre garantie de satisfaction garantit que vous trouverez toujours un document d'étude qui vous convient. Vous remplissez un formulaire et notre équipe du service client s'occupe du reste.

Auprès de qui est-ce que j'achète ce résumé ?

Stuvia est une place de marché. Alors, vous n'achetez donc pas ce document chez nous, mais auprès du vendeur DCsss. Stuvia facilite les paiements au vendeur.

Est-ce que j'aurai un abonnement?

Non, vous n'achetez ce résumé que pour €7,16. Vous n'êtes lié à rien après votre achat.

Peut-on faire confiance à Stuvia ?

4.6 étoiles sur Google & Trustpilot (+1000 avis)

52510 résumés ont été vendus ces 30 derniers jours

Fondée en 2010, la référence pour acheter des résumés depuis déjà 14 ans

Commencez à vendre!
€7,16
  • (0)
Ajouter au panier
Ajouté